Latest Breaking News On - Susan pietropaolo - Page 4 : comparemela.com

Company to Hold Clinical Update Webcast; Details ForthcomingSAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for post

United statesAptose biosciencesSusan pietropaoloCompany to hold clinical update webcastInternational conferenceCorporate communications investor relationsAptose biosciences incExchange commissionEuropean school of haematologyHold clinical update webcastEuropean schoolAcute myeloid leukemiaMyeloid kinase inhibitor safetyUnited states securitiesAptose biosciences incAcute myeloid leukemia